BioCryst Pharmaceuticals announced that the Canadian Agency for Drugs and Technologies in Health, or CADTH, Canadian Drug Expert Committee, or CDEC, has issued a positive recommendation for Orladeyo to be reimbursed for the routine prevention of attacks of hereditary angioedema, or HAE, in adults and pediatric patients 12 years of age and older.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst presents new long-term, real-world data on ORLADEYO
- BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)